<SEC-DOCUMENT>0001144204-18-019308.txt : 20180405
<SEC-HEADER>0001144204-18-019308.hdr.sgml : 20180405
<ACCEPTANCE-DATETIME>20180405061101
ACCESSION NUMBER:		0001144204-18-019308
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180331
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180405
DATE AS OF CHANGE:		20180405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		18739293

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv490449_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%; text-align: center">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%; text-align: center">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;&nbsp;</B>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%; text-align: center">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
March 31, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Applied
DNA Sciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction<BR>
        of incorporation)</P></TD>
    <TD STYLE="width: 36%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 32%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). Emerging growth company&nbsp;
</FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;
</FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 7.01.</B></TD><TD STYLE="text-align: justify"><B>Entry into a Material Definitive Agreement.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2018, Applied DNA Sciences,
Inc. (the &ldquo;Company&rdquo;) entered into a License and Cooperation Agreement and a related Supply Agreement (the &ldquo;Agreements&rdquo;)
effective March 31, 2018, with Colorcon, Inc. (&ldquo;Colorcon&rdquo;) for the use of the Company&rsquo;s SigNature<SUP>&reg;
</SUP>molecular tags in Colorcon&rsquo;s pharmaceutical and neutraceutical product offerings and access to the Company&rsquo;s
associated authentication technologies. The Company issued a press release announcing the Agreements on April 5, 2018. A copy
of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibit 99.1 shall not be deemed &ldquo;filed&rdquo; for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the
liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the
Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>d)</I></FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exhibits</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt; font-size: 10pt"><A HREF="tv490449_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>99.1</U></FONT></A></TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><A HREF="tv490449_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Press
    Release of Applied DNA Sciences, Inc. dated April 5, 2018 announcing agreements with Colorcon, Inc.</U></FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 5, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; padding-right: 0.8pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 88%; padding-right: 0.8pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><A HREF="tv490449_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>99.1</U></FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><A HREF="tv490449_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Press
    Release of Applied DNA Sciences, Inc. dated April 5, 2018 announcing agreements with Colorcon, Inc.</U></FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv490449_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Applied DNA Signs Definitive Agreements
with Colorcon</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">for Molecular Tagging in the Pharmaceutical and Nutraceutical Markets</P>

<P STYLE="color: #0070C0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="color: #0070C0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Includes Milestone Payments.
Long-Term Licensing Royalties to be Paid to Applied DNA Following Sales.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STONY BROOK, N.Y. , April 5, 2018 &ndash; Applied DNA Sciences,
Inc., (NASDAQ: APDN) (&ldquo;Applied DNA&rdquo; or the &ldquo;Company,&rdquo;) has signed a License and Cooperation Agreement
and a related Supply Agreement (collectively known as the &ldquo;Agreements&rdquo;), effective March 31, 2018, with Colorcon,
Inc. (&ldquo;Colorcon&rdquo;) for the use of Applied DNA&rsquo;s SigNature<SUP>&reg;</SUP> molecular tags in Colorcon&rsquo;s
product offerings and access to the Company&rsquo;s associated authentication technologies. These Agreements follow the memorandum
of understanding (MOU) announced on December 18, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Agreements, Applied DNA grants Colorcon
exclusive worldwide right to use the Company&rsquo;s molecular tags and associated authentication technologies in film coatings
for solid oral dosage form (&ldquo;SOD&rdquo;) applications, for which Colorcon is the largest global supplier, and non-exclusive
rights to use the Company&rsquo;s technologies in inks and colorants for SOD applications. Pursuant to the Agreements, Applied
DNA will supply taggant and authentication materials to Colorcon in exchange for long-term royalties on the sale of Colorcon products
incorporating the Company&rsquo;s molecular tags and on the sale of authentication services related thereto. Further, the first
of two milestone payments is payable to Applied DNA with the signing of the Agreements. The Company will receive the second milestone
payment upon initial approval by a regulatory authority for application in a SOD pharmaceutical or nutraceutical product application. The Agreements generally expire on the later of October 1, 2032 or the last expiration date
of any patent licensed pursuant to the Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;With the signing of these definitive agreements and Colorcon&rsquo;s
industry-leading role, we demonstrate our continuing ability to monetize our DNA molecular taggant platform and associated services
to drive revenue growth. The seamless solution integrating our molecular tag with Colorcon's film coatings puts us on a path to
adoption by Colorcon&rsquo;s current and prospective pharmaceutical customers.&rdquo;, stated Dr. James Hayward, President and
CEO of Applied DNA. Dr. Hayward added that: &ldquo;Molecular tags will provide traceability for audits and law enforcement and,
perhaps most importantly, forensic confirmation of the authenticity of the drug product to the patient and all those in the supply
chain, including the pharmacist, the drug distributors and manufacturers. We are gratified to be working with a world leader
whose sales channel greatly amplifies our combined access to the market.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Our teams are already actively engaged in discussions
with potential customers,&rdquo; stated Kelly Boyer, General Manager Film Coatings Business Unit for Colorcon, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms Boyer continued, &ldquo;Colorcon has an established reputation
for innovation and service. Applied DNA&rsquo;s SigNature molecular tags and authentication technologies provide value-addition
at a time when regulators are demanding that the industry implement serialization in order to track packaging. The collaboration
goes a significant step further by enabling traceability at the level of single unit, solid oral doses, and it is complementary
to the provisions of the <U>Drug Supply Chain Security Act</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Colorcon has team members with extensive experience in global
regulatory compliance, while Applied DNA has the benefit of several of its management team with experience in the pharmaceutical
industry, and the Company has already scaled to supply large, global commercial ecosystems. Applied DNA&rsquo;s Molecular Tags
have been included in over 200 million pounds of cotton, over 15 million pounds of synthetic fibers, and over 800,000 microcircuits
for the Department of Defense. The Company&rsquo;s data portals, supporting hundreds of thousands of data transactions per day,
have stored over 300,000 sample testing reports, and are now exchanging data with multiple third-party platforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Colorcon<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Colorcon is a world leader in the development,
supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the
pharmaceutical industry. Colorcon&rsquo;s best-in-class products and technologies are complemented by Colorcon&rsquo;s extensive
application data and value-added services to support all phases of solid oral dose design and development. Colorcon&rsquo;s focus
on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice.
That reputation is based on the superior product quality, unparalleled technical support, extensive regulatory assistance and reliable
supply from multiple locations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA is a provider of molecular
technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass
production for diagnostics, personalized medicine and therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Applied DNA makes life real and safe
by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply
chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The
proprietary DNA-based &quot;CertainT<SUP>&reg;</SUP>&quot; platform can be used to identify, tag, test, and track products, to
help assure authenticity, origin, traceability, sustainability and quality of products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">SigNature<SUP>&reg;</SUP> DNA describes
the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions, targeted
a wide range of industries, including but not limited to, pharmaceuticals and nutraceuticals, textiles and defense materials ,
BackTrac<SUP>&reg;</SUP> and DNAnet<SUP>&reg;</SUP>, for anti-theft and loss prevention, and digitalDNA<SUP>&reg;</SUP>, providing
powerful track-and-trace. Our products provide a forensic chain of evidence in large commercial ecosystems</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Visit&nbsp;adnas.com&nbsp;for more
information. Follow us on&nbsp;Twitter&nbsp;and&nbsp;LinkedIn. Join our&nbsp;mailing list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; background-color: white"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements made by Applied DNA in this press release may
be &ldquo;forward-looking&rdquo; in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking
statements describe Applied DNA&rsquo;s future plans, projections, strategies and expectations, and are based on assumptions and
involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially
from those projected due to our lack of significant revenues, limited financial resources, limited market acceptance, history of
net losses, market competition, risk of not obtaining regulatory approval and various other factors detailed from time to time
in Applied DNA&rsquo;s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent
quarterly report on Form 10-Q filed on February 8, 2018, which are available at&nbsp;www.sec.gov. Applied DNA undertakes no obligation
to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to
reflect the occurrence of unanticipated&nbsp;events, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investor
contact: </B></FONT>Sanjay M. Hurry<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>,</B></FONT> LHA Investor Relations<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>,
</B></FONT>212-838-3777, shurry@lhai.com<BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>media contact: </B></FONT>Cheryl Schneider, DGI Comm, 212-825-3210,
cschneider@dgicomm.com<BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>program contact: </B></FONT>James A. Hayward, Chief Executive Officer,
(631) 240-8800 james.hayward@adnas.com<BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>web:&nbsp;</B></FONT><U>www.adnas.com</U><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>twitter: </B></FONT>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K L\# 2(  A$! Q$!_\0
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MJ4EPMP;>-XS@VR[A+#R>'!Z].&'![9ZTW6-9GM+^&QM(P97B:9I&ADE55!
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MO?\ OT:?^S_W?P)_?^?XC3XEUW_H,7W_ '^-,/B;7O\ H,WW_?XT\^&->_Z
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MU_PBNCR:?]J^T[[F2??LV8WG.,9/2M^B@ HHHH **** "BBB@ HHHH ****
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K L\# 2(  A$! Q$!_\0
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MJ4EPMP;>-XS@VR[A+#R>'!Z].&'![9ZTW6-9GM+^&QM(P97B:9I&ADE55!
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MO?\ OT:?^S_W?P)_?^?XC3XEUW_H,7W_ '^-,/B;7O\ H,WW_?XT\^&->_Z
MU[_WZ--/A?7_ /H#7W_?DU5\/_=_ E^W\_Q&'Q/KV?\ D,WW_?XTT^)]?_Z#
M5]_W^-//A?7\_P#(&OO^_)IO_"+>(/\ H"WW_?DT_P#9_P"[^ OW_P#>_$C/
MBC7\_P#(:O\ _O\ &FGQ3X@_Z#5__P!_C3SX5\09_P"0+??]^333X5\0_P#0
M$O\ _OR:=\-_=_ 7[_\ O?B,/BKQ#_T&[_\ [_FI+7QAXC@N5D76;MR,C;(^
M]3QZ&F'PIXA_Z E__P!^34EKX-\1SW*QKHUVA.3ND38HX]33?U6VO+^ E]8O
MIS?B?0M8&O\ AO\ MO5]"O\ [5Y/]E7)N-FS=YF1C&<\?K6_17R9]4%8'A#P
MU_PBNCR:?]J^T[[F2??LV8WG.,9/2M^B@ HHHH **** "BBB@ HHHH ****
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K L\# 2(  A$! Q$!_\0
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MJ4EPMP;>-XS@VR[A+#R>'!Z].&'![9ZTW6-9GM+^&QM(P97B:9I&ADE55!
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MO?\ OT:?^S_W?P)_?^?XC3XEUW_H,7W_ '^-,/B;7O\ H,WW_?XT\^&->_Z
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MU_PBNCR:?]J^T[[F2??LV8WG.,9/2M^B@ HHHH **** "BBB@ HHHH ****
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5** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
